The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

However, their role in ensuring long-term immunity or offering an advantage against future infections remains to be clarified. Systemic Lupus Erythematosus (SLE)—lupus for short—is a chronic ...

However, their role in ensuring long-term immunity or offering an advantage against future infections remains to be clarified. Systemic Lupus Erythematosus (SLE)-lupus for short-is a chronic ...

GSE138458 is a dataset containing 307 SLE patient samples and 23 healthy samples. The whole blood samples were obtained from the Oklahoma Medical Research Foundation ... The GO was interpreted in ...

Finding it hard to breathe when you lay down is medically called orthopnea. Find a list of potential causes to help narrow down your overall risk here.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S.

Dr. Baker added, "Artiva is pioneering novel NK cell therapies with unmatched versatility and broad expansion potential across autoimmune diseases. I look forward to partnering with the management ...